Phathom Pharmaceuticals Inc (PHAT)

Form 8-K - Current report

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline...

Form 4 - Statement of changes in beneficial ownership of securities

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28...

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

~1.35 million total VOQUEZNA® prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase...

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements